TipRanks
Verastem (DE:2VSA)
FRANKFURT:2VSA
Germany Market
2VSA
Verastem
RESEARCH TOOLSreports

Verastem (2VSA) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

2VSA Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Verastem
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2VSA Stock 12 Month Forecast

Average Price Target

€13.39
▲(116.98% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Verastem in the last 3 months. The average price target is €13.39 with a high forecast of €16.07 and a low forecast of €10.71. The average price target represents a 116.98% change from the last price of €6.17.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","17":"€17","5.75":"€5.75","9.5":"€9.5","13.25":"€13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.06507434,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.38756195,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.71004956,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.71</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.75,9.5,13.25,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,7.678851872307693,8.377703744615385,9.076555616923077,9.77540748923077,10.474259361538461,11.173111233846154,11.871963106153846,12.570814978461538,13.26966685076923,13.968518723076922,14.667370595384615,15.366222467692307,{"y":16.06507434,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,7.472889380769232,7.965778761538462,8.458668142307692,8.951557523076923,9.444446903846154,9.937336284615386,10.430225665384615,10.923115046153846,11.416004426923077,11.908893807692309,12.40178318846154,12.89467256923077,{"y":13.38756195,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,7.26692688923077,7.553853778461539,7.840780667692308,8.127707556923077,8.414634446153846,8.701561335384616,8.988488224615384,9.275415113846154,9.562342003076923,9.849268892307693,10.136195781538461,10.423122670769231,{"y":10.71004956,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.54,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.552,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.305,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.923,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.854,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€16.07Average Price Target€13.39Lowest Price Target€10.71
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:2VSA
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
€16.07
Buy
160.37%
Upside
Reiterated
10/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (NASDAQ: VSTM), Ultragenyx Pharmaceutical (NASDAQ: RARE) and UnitedHealth (NYSE: UNH)
RBC Capital Analyst forecast on DE:2VSA
Leonid Timashev
RBC Capital
RBC Capital
€12.5
Buy
102.51%
Upside
Reiterated
10/08/26
RBC Capital Remains a Buy on Verastem (VSTM)
BTIG Analyst forecast on DE:2VSA
Jeet Mukherjee
BTIG
BTIG
€16.07
Buy
160.37%
Upside
Reiterated
10/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on DE:2VSA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Buy
―
Initiated
09/17/26
Verastem initiated with an Outperform at Wolfe ResearchVerastem initiated with an Outperform at Wolfe Research
Mizuho Securities Analyst forecast on DE:2VSA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
€12.5→€11.6
Buy
88.05%
Upside
Reiterated
08/10/26
Verastem price target lowered to $13 from $14 at MizuhoVerastem price target lowered to $13 from $14 at Mizuho
Guggenheim Analyst forecast on DE:2VSA
Michael Schmidt
Guggenheim
Guggenheim
€12.5→€10.71
Buy
73.58%
Upside
Reiterated
08/06/26
Verastem price target lowered to $12 from $14 at GuggenheimVerastem price target lowered to $12 from $14 at Guggenheim
Alliance Global Partners Analyst forecast on DE:2VSA
James Molloy
Alliance Global Partners
Alliance Global Partners
€16.07
Buy
160.37%
Upside
Reiterated
06/24/26
Verastem (VSTM) Gets a Buy from Alliance Global Partners
Jefferies Analyst forecast on DE:2VSA
Faisal Khurshid
Jefferies
Jefferies
€13.39→€7.14
Buy
15.72%
Upside
Reiterated
06/23/26
Verastem price target lowered to $8 from $15 at JefferiesVerastem price target lowered to $8 from $15 at Jefferies
B. Riley Securities Analyst forecast on DE:2VSA
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
€14.28
Buy
131.44%
Upside
Initiated
05/22/26
Verastem (VSTM) Receives a Buy from B. Riley Securities
Cantor Fitzgerald Analyst forecast on DE:2VSA
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
10/16/25
Verastem assumed with an Overweight at Cantor FitzgeraldVerastem assumed with an Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:2VSA
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
€16.07
Buy
160.37%
Upside
Reiterated
10/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (NASDAQ: VSTM), Ultragenyx Pharmaceutical (NASDAQ: RARE) and UnitedHealth (NYSE: UNH)
RBC Capital Analyst forecast on DE:2VSA
Leonid Timashev
RBC Capital
RBC Capital
€12.5
Buy
102.51%
Upside
Reiterated
10/08/26
RBC Capital Remains a Buy on Verastem (VSTM)
BTIG Analyst forecast on DE:2VSA
Jeet Mukherjee
BTIG
BTIG
€16.07
Buy
160.37%
Upside
Reiterated
10/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on DE:2VSA
Kalpit Patel
Wolfe Research
Wolfe Research
―
Buy
―
Initiated
09/17/26
Verastem initiated with an Outperform at Wolfe ResearchVerastem initiated with an Outperform at Wolfe Research
Mizuho Securities Analyst forecast on DE:2VSA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
€12.5→€11.6
Buy
88.05%
Upside
Reiterated
08/10/26
Verastem price target lowered to $13 from $14 at MizuhoVerastem price target lowered to $13 from $14 at Mizuho
Guggenheim Analyst forecast on DE:2VSA
Michael Schmidt
Guggenheim
Guggenheim
€12.5→€10.71
Buy
73.58%
Upside
Reiterated
08/06/26
Verastem price target lowered to $12 from $14 at GuggenheimVerastem price target lowered to $12 from $14 at Guggenheim
Alliance Global Partners Analyst forecast on DE:2VSA
James Molloy
Alliance Global Partners
Alliance Global Partners
€16.07
Buy
160.37%
Upside
Reiterated
06/24/26
Verastem (VSTM) Gets a Buy from Alliance Global Partners
Jefferies Analyst forecast on DE:2VSA
Faisal Khurshid
Jefferies
Jefferies
€13.39→€7.14
Buy
15.72%
Upside
Reiterated
06/23/26
Verastem price target lowered to $8 from $15 at JefferiesVerastem price target lowered to $8 from $15 at Jefferies
B. Riley Securities Analyst forecast on DE:2VSA
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
€14.28
Buy
131.44%
Upside
Initiated
05/22/26
Verastem (VSTM) Receives a Buy from B. Riley Securities
Cantor Fitzgerald Analyst forecast on DE:2VSA
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
10/16/25
Verastem assumed with an Overweight at Cantor FitzgeraldVerastem assumed with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verastem

3 Months
Leonid TimashevRBC Capital
Success Rate
8/15 ratings generated profit
53%
Average Return
+23.60%
Copying Leonid Timashev's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +23.60% per trade.
1 Year
Leonid TimashevRBC Capital
Success Rate
12/15 ratings generated profit
80%
Average Return
+24.33%
Copying Leonid Timashev's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +24.33% per trade.
2 Years
Leonid TimashevRBC Capital
Success Rate
13/15 ratings generated profit
87%
Average Return
+37.47%
Copying Leonid Timashev's trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +37.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2VSA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
22
19
15
9
12
Buy
0
0
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
19
15
10
13
In the current month, 2VSA has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2VSA average Analyst price target in the past 3 months is 13.39.
Each month's total comprises the sum of three months' worth of ratings.

2VSA Financial Forecast

2VSA Earnings Forecast

Next quarter’s earnings estimate for 2VSA is -€0.41 with a range of -€0.54 to -€0.37. The previous quarter’s EPS was -€0.31. 2VSA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2VSA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2VSA is -€0.41 with a range of -€0.54 to -€0.37. The previous quarter’s EPS was -€0.31. 2VSA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2VSA has Performed in-line its overall industry.

2VSA Sales Forecast

Next quarter’s sales forecast for 2VSA is €26.03M with a range of €23.72M to €27.65M. The previous quarter’s sales results were €35.74M. 2VSA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2VSA has Performed in-line its overall industry.
Next quarter’s sales forecast for 2VSA is €26.03M with a range of €23.72M to €27.65M. The previous quarter’s sales results were €35.74M. 2VSA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2VSA has Performed in-line its overall industry.

2VSA Stock Forecast FAQ

What is DE:2VSA’s average 12-month price target, according to analysts?
Based on analyst ratings, Verastem’s 12-month average price target is 13.39.
    What is DE:2VSA’s upside potential, based on the analysts’ average price target?
    Verastem has 116.98% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Verastem a Buy, Sell or Hold?
          Verastem has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Verastem’s share price target?
            The average share price target for Verastem is 13.39. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €16.07 ,and the lowest forecast is €10.71. The average share price target represents 116.98% Increase from the current price of €6.17.
              What do analysts say about Verastem?
              Verastem’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Verastem?
                To buy shares of DE:2VSA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.